Big money is pouring into two disruptive segments in two of the world’s biggest industries - healthcare and energy.
Both these have been undergoing continual digital disruption …
But there’s more to come.
In healthcare and wellness, global VC funding for digital health companies hit $15 billion in the first half of this year... and $19 billion if you include public market financing and debt. And now, we’re looking at artificial intelligence that empowers consumers to take control of their healthcare with a stunning new app that is trained by doctors to think like a doctor.
In energy, there are few segments as exciting as hydrogen. There is projected to be $500 billion in new investment in hydrogen through 2030. Over 130 large-scale hydrogen projects have been announced just since February this year, adding up to a total of nearly 360 projects.
Hydrogen has a major advantage over other energy sources because it burns hot and clean and has the potential to cut 20% of global industrial carbon emissions, and could even replace coal, according to Bloomberg.
This will hit the big time as soon as it can be produced for $1 a kilogram - it’s competitive price point. That’s why all the big money is rushing into this. BNEF estimates it will reach that price level by 2030.
That leaves us with 2 stocks with high disruption potential in 2 key sectors this year:
#1 Brookfield Renewable Partners LP (NYSE:BEP)
Brookfield is a great way to get in on hydrogen without risking everything on a clean energy savior that could be commercially competitive by 2030.
Brookfield is a global giant when it comes to renewables, and hydrogen is its newest game. This time last year, Brookfield joined forces with one of the most exciting pure-play hydrogen fuel cell stocks, Plug Power (NASDAQ:PLUG). PLUG has had its ups and down, and might now be entering another new phase of reward for investors, but it’s Brookfield that is the steady climber in the sector.
Hydrogen only adds to an already huge portfolio of thousands of power-generating assets. And when it cracks hydrogen, too, especially the green variety, there will be no stopping it.
BEP is trading lower this year, despite the fact that it is one of the biggest players on the renewable energy scene--and one of the smartest. That makes it a good time to buy, while soaring oil and gas prices are distracting everyone from future realities.
When the commercial hydrogen code is finally cracked--and again, Bloomberg thinks that will be by 2030--BEP will be one to come out on top.
But even without hydrogen, keep this in mind: Brookfield’s global collection of hydroelectric power plants accounts for half of its revenue. And that’s preferable to solar and wind right now because hydropower isn’t intermittent. Furthermore, that nice revenue base is catapulting Brookfield into other areas of clean energy.
#2 Treatment.com International Inc. (CSE: TRUE)
The second stock on our big industry disruption list is Treatment.com, one of the most interesting fixes for a very broken American healthcare system. And the timing is perfect on this one: Treatment.com is about to launch its groundbreaking AI app: Cara, powered by its unique Global Library of Medicine (GLM).
Cara is the most sophisticated AI targeting the symptom checking market because it has been trained by a global team of doctors to think like a doctor and provide consumers with a way to truly diagnose their symptoms without relying on the fear mongering of “Dr. Google”, the cookie-cutter search engine of WebMD or the dangerous medical advice floating around TikTok.
Cara makes personalized health assessments and wellness management based on data from actual doctors as easy as clicking a few buttons … without stepping into a doctor’s office, or paying for a doctor’s visit. It’s absolutely free.
How does it work?
The AI behind it might be highly sophisticated and complex, but from a user’s perspective, nothing could be simpler: Cara asks you questions about your symptoms and then sorts through millions of pieces of information. It covers your historical medical cases, demographic data and continual advances in medical knowledge.
It can all be integrated with Apple Health Kit, Apple Watch, and FitBit .. but the biggest note of confidence in the new AI that seems ready to disrupt healthcare as we know it is this: The hundreds of doctors who trained it made it so good that it’s been licensed to test medical students at the University of Minnesota’s Medical School.
The app industry is one of the cleanest out there when it comes to costs and revenues …
For apps, the big costs are all taken care of upfront, with development. After that, it’s all about revenues, not costs.
While the initial basic Cara app is free, premium app subscriptions will be just one revenue stream. Specialized medical segments come with a subscription, and Cara has a line-up planned after the launch.
But Cara AI connects everything: wellness, telemedicine, pharma, and health products. That means there’s value in health and wellness products, too, as well as in connecting users to the best telemedicine offerings.
What investors should be latching onto most, though, is the massive amounts of data Cara will be collecting from users. That health data, along with Cara’s artificial intelligence IP, make it potentially worth multiple times more than just another app.
Everyone will want this data … governments, healthcare providers, insurance companies, pharmacies … and quite possibly, those soaring telemedicine businesses that have become the kings of our post-COVID environment.
In just three years from now, market predictions see healthcare big data hitting $68 billion .
That’s a huge number to tap into for a small Canadian company that just listed publicly in April. WebMD, the most popular “symptom checker” out there, is worth $2.8 billion, without any artificial intelligence … without any personalized healthcare assessments … and without any attempt to think like a doctor.
Demand for AI that can help us manage our health and check our symptoms without going to the doctor first, is voracious. Cara is the answer to that demand, and the first to offer AI trained by doctors.
After Cara launches later this year, this $170M market cap company could become valued at multiples higher.
Other companies working to transform the healthcare industry:
Premium Brand Holdings (TSX:PBH) caters to the food manufacturing industry with a focus on
healthy, organic and sustainable ingredients. They offer niche brands that compete in the natural and specialty foods markets as well as established national brands. Their portfolio includes high-quality products including gourmet organic coffee, all-natural protein supplements, gluten free crackers and nut butters.
Premium Brand Holdings is dedicated to delivering their customers with an exceptional customer experience by providing them with premier products at competitive prices while maintaining an ethical approach to business practices. Its commitment is to provide a safe environment for consumers of all ages through sound quality assurance standards and strict adherence to federal regulations governing product safety. Premium Brands Holdings also takes pride in its contributions towards sustainability by offering environmentally friendly packaging solutions.
Trillium Therapeutics Inc. (TSX:TRIL) is a specialized biotechnology company that takes a unique approach on the industry, harnessing insights from nature to develop novel immunotherapies to treat cancer. Trillium’s products tackle such diseases as lymphoma and myeloma and other blood cancers.
Though Trillium is still young compared to some of its peers, the company has already carved out a name for itself in this industry. Though Trillium has faced some resistence this year, the company still has a ton of potential, and lots of exciting new developments in its pipeline.
Oncolytics Biotech Inc. (TSX:ONC) is another Canadian biotech firm. The company got it start from a major series of discoveries based out of the University of Calgary and has grown significantly over the past two decades. Onoclytics’ primary product is REOLYSIN, a first-in-class, systemically administered, immuno-oncolytic virus created with the potential to act as a therapy for cancer patients.
3D Signatures Inc (CVE:DXD) is a high-tech Canadian firm that has found itself in the center of two explosive sectors. It’s armed with an innovative new software platform which uses 3D analysis to target various diseases and help clinicians identify a diagnosis and optimize treatment plans. 3D Signatures’ software is saving doctors time which could be the difference of life and death for some patients. 3D Signatures sets itself apart from its competition through creating individualized treatment plans for patients. Using its mapping platform, the software can determine how a disease will progress and whether or not the patient will respond to treatment
3D Signatures’ broad scope and futuristic technology brings a promising opportunity to potential investors. It truly is at the forefront of a new era in medicine, and investors should not overlook this company’s massive potential.
CRH Medical Corporation (TSX:CRH) specializes in products and services designed for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. With a long history within the space, CRH has positioned itself as a leader in the field, trusted by medical professionals all over the world.
CRH also made a majpr acquisition at the beginning of the year, buying out Anesthesia Care Associates, LLC, an Indiana-based gastroenterology anesthesia practice. The estimated $2.6 million deal will increase CRH’s footprint in the space, and has been well received by investors.
By. Michael Kern
** IMPORTANT NOTICE AND DISCLAIMER -- PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT. This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.